These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38672625)

  • 1. Predicting Isocitrate Dehydrogenase Status in Non-Contrast-Enhanced Adult-Type Astrocytic Tumors Using Diffusion Tensor Imaging and
    Yasuda S; Yano H; Ikegame Y; Ikuta S; Maruyama T; Kumagai M; Muragaki Y; Iwama T; Shinoda J; Izumo T
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system.
    Takei H; Shinoda J; Ikuta S; Maruyama T; Muragaki Y; Kawasaki T; Ikegame Y; Okada M; Ito T; Asano Y; Yokoyama K; Nakayama N; Yano H; Iwama T
    J Neurosurg; 2020 Oct; 133(4):1010-1019. PubMed ID: 31419796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of
    Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
    J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of astrocytoma between grades II and III using a combination of methionine positron emission tomography and magnetic resonance spectroscopy.
    Yano H; Miwa K; Nakayama N; Maruyama T; Ohe N; Ikuta S; Ikegame Y; Yamada T; Takei H; Owashi E; Ohmura K; Yokoyama K; Kumagai M; Muragaki Y; Iwama T; Shinoda J
    World Neurosurg X; 2023 Jul; 19():100193. PubMed ID: 37123626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [
    Chen Q; Wang K; Ren X; Zhao X; Chen Q; Fan D; Zhang S; Li X; Ai L
    J Neurooncol; 2023 Dec; 165(3):547-559. PubMed ID: 38095773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET.
    Wang Y; Fushimi Y; Arakawa Y; Shimizu Y; Sano K; Sakata A; Nakajima S; Okuchi S; Hinoda T; Oshima S; Otani S; Ishimori T; Tanji M; Mineharu Y; Yoshida K; Nakamoto Y
    Jpn J Radiol; 2023 Nov; 41(11):1255-1264. PubMed ID: 37219717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
    Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
    Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas.
    Kong Z; Zhang Y; Liu D; Liu P; Shi Y; Wang Y; Zhao D; Cheng X; Wang Y; Ma W
    Ann Nucl Med; 2021 Apr; 35(4):493-503. PubMed ID: 33532992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas.
    Yano H; Ikegame Y; Miwa K; Nakayama N; Maruyama T; Ikuta S; Yokoyama K; Muragaki Y; Iwama T; Shinoda J
    Cureus; 2022 Jul; 14(7):e27157. PubMed ID: 36017268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive role of magnetic resonance imaging in the distinction of isocitrate dehydrogenase (IDH) mutant grade 4 astrocytomas versus glioblastomas.
    Halefoglu AM; Camurcuoglu E; Tanik C; Kizilkaya O; Yilmaz A
    Acta Radiol; 2023 Jun; 64(6):2074-2086. PubMed ID: 37038636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative
    Unterrainer M; Fleischmann DF; Vettermann F; Ruf V; Kaiser L; Nelwan D; Lindner S; Brendel M; Wenter V; Stöcklein S; Herms J; Milenkovic VM; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1368-1380. PubMed ID: 31486876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.
    Suzuki K; Kawai N; Ogawa T; Miyake K; Shinomiya A; Yamamoto Y; Nishiyama Y; Tamiya T
    EJNMMI Res; 2021 Jul; 11(1):67. PubMed ID: 34291337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-high b-value DWI accurately identifies isocitrate dehydrogenase genotypes and tumor subtypes of adult-type diffuse gliomas.
    Wang X; Shu X; He P; Cai Y; Geng Y; Hu X; Sun Y; Xiao H; Zheng W; Song Y; Xue Y; Jiang R
    Eur Radiol; 2024 Oct; 34(10):6751-6762. PubMed ID: 38528135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of [
    Shymanskaya A; Worthoff WA; Stoffels G; Lindemeyer J; Neumaier B; Lohmann P; Galldiks N; Langen KJ; Shah NJ
    Mol Imaging Biol; 2020 Feb; 22(1):198-207. PubMed ID: 30989437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Apparent Diffusion Coefficient Histogram Analysis:Differentiation of Genetic Subtypes of Diffuse Lower-grade Gliomas].
    Liu D; Xu JM; Liao HF; Wen M
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Aug; 42(4):444-451. PubMed ID: 32895095
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.